Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.

JAMA Neurology
Ludwig KapposStephen L Hauser

Abstract

Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA regarded as a feature of primary and secondary progressive multiple sclerosis. To investigate the contributions of relapse-associated worsening vs relapse-independent progression to overall confirmed disability accumulation (CDA) and assess respective baseline prognostic factors and outcomes of 2 treatments. Analyses occurred from July 2015 to February 2020 on pooled data from the intention-to-treat population of 2 identical, phase 3, multicenter, double-blind, double-dummy, parallel-group randomized clinical trials (OPERA I and II) conducted between August 2011 and April 2015. In the trials, patients with relapsing multiple sclerosis (RMS), diagnosed using the 2010 revised McDonald criteria, were randomized from 307 trial sites in 56 countries; resulting data were analyzed in the pooled data set. Participants were randomized 1:1 to receive 600 mg of ocrelizumab by intravenous infusion every 24 weeks or subcutaneous interferon β-1a 3 times a week at a dose of 44 μg throughout a 96-week treatment period. Confirmed disability accumulation was defined by an increas...Continue Reading

References

Jan 29, 1998·The New England Journal of Medicine·B D TrappL Bö
Mar 23, 2006·Annual Review of Immunology·Flavius Martin, Andrew C Chan
Dec 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·David J DiLilloThomas F Tedder
Mar 10, 2011·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Dec 24, 2011·Journal of Neurology, Neurosurgery, and Psychiatry·Douglas S GoodinUNKNOWN 16-Year Long Term Follow-up Study Investigators
Mar 16, 2013·MAbs·Christian KleinGerhard Niederfellner
Mar 29, 2014·Multiple Sclerosis : Clinical and Laboratory Research·J ZhangD Leppert
May 30, 2014·Neurology·Fred D LublinChris H Polman
Jan 23, 2015·Annals of Neurology·Sabine PfeifenbringWolfgang Brück
Mar 24, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Diego CadavidDaniel Mikol
May 5, 2016·Annals of Neurology·Vilija G JokubaitisUNKNOWN MSBase Study Group
Jun 1, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Andrew Chan, Ralf Gold
Jul 13, 2016·Brain : a Journal of Neurology·Johannes LorscheiderUNKNOWN MSBase Study Group
Jul 28, 2016·Annals of Neurology·UNKNOWN University of California, San Francisco MS-EPIC Team:Stephen L Hauser
Dec 22, 2016·The New England Journal of Medicine·Stephen L HauserUNKNOWN OPERA I and OPERA II Clinical Investigators
Dec 22, 2016·The New England Journal of Medicine·Xavier MontalbanUNKNOWN ORATORIO Clinical Investigators
May 31, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Ludwig KapposUNKNOWN Tysabri® Observational Program (TOP) Investigators
Mar 24, 2018·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Eva HavrdováGavin Giovannoni
Apr 20, 2019·Multiple Sclerosis and Related Disorders·Nils Koch-HenriksenMelinda Magyari

❮ Previous
Next ❯

Citations

Jun 12, 2020·Der Nervenarzt·Jonas GrafHans-Peter Hartung
Sep 26, 2020·Multiple Sclerosis and Related Disorders·Hernan InojosaTjalf Ziemssen
Feb 9, 2021·Frontiers in Neurology·Hernan InojosaTjalf Ziemssen
Feb 11, 2021·Life·Ruggiero SecciaFrancesca Grassi
Nov 17, 2020·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Gabriel BstehThomas Berger
Feb 25, 2021·Human Brain Mapping·Charidimos TsagkasStefano Magon
Mar 4, 2021·Der Nervenarzt·Olaf Hoffmann, Ralf Gold
Mar 7, 2021·Journal of Clinical Medicine·Katarzyna Kapica-TopczewskaAlina Kułakowska
Mar 26, 2021·Frontiers in Neurology·Tjalf ZiemssenUlf Schulze-Topphoff
Apr 21, 2021·Multiple Sclerosis : Clinical and Laboratory Research·Antonio Scalfari
Apr 21, 2021·Multiple Sclerosis : Clinical and Laboratory Research·K Schmierer, G Giovannoni
Apr 22, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Esther S FrischMartin S Weber
Feb 2, 2021·Annual Review of Immunology·Valeria RamagliaJennifer L Gommerman
Mar 13, 2021·Current Opinion in Neurology·Sarah B SimmonsDaniel Ontaneda
Apr 10, 2021·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Anna Isabella PisaniMassimiliano Calabrese
Jun 12, 2021·Multiple Sclerosis and Related Disorders·Nils Koch-HenriksenMelinda Magyari
Jul 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Dániel SandiLászló Vécsei
Jul 24, 2021·Der Nervenarzt·Heinz WiendlUNKNOWN die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG)
Jul 15, 2021·Multiple Sclerosis : Clinical and Laboratory Research·Xavier MontalbanStephen L Hauser
Jul 4, 2021·Annals of Neurology·Stephen L Hauser
Aug 1, 2021·Multiple Sclerosis and Related Disorders·M MarrodanM C Ysrraelit
Aug 11, 2021·Neurology. Neuroimmunology and Neuroinflammation·Luca ProsperiniClaudio Gasperini
Jun 6, 2021·Neurology·Bruce A C CreeHans Lassmann
Aug 25, 2021·Der Nervenarzt·Ralf A Linker, Ralf Gold
Aug 24, 2021·Therapeutic Advances in Neurological Disorders·Heinz WiendlUNKNOWN ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG)
Sep 4, 2021·Multiple Sclerosis : Clinical and Laboratory Research·Christian Enzinger
Sep 4, 2021·Multiple Sclerosis : Clinical and Laboratory Research·Douglas L ArnoldColm Elliott
Sep 28, 2021·Expert Review of Clinical Immunology·Deja R RoseDaniel Ontaneda
Jun 29, 2021·Brain : a Journal of Neurology·Stefan BittnerFrauke Zipp
Dec 22, 2021·Human Brain Mapping·Yael BacknerNetta Levin
Dec 24, 2021·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Svenja KlinsingChristian Foerch
Feb 3, 2022·Expert Review of Clinical Immunology·G Dalla CostaG Comi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved